Prescribing information packets1 for Food and Drug Administration (FDA) approved chemotherapy drugs contain important pharmacological and chemical data such as, chemical structure, water solubility, and ADME/tox (absorption, distribution, metabolism, excretion, and toxicity) properties. In this project2,3 we evaluated 85 FDA cancer drug profiles, extracted various pharmacokinetic properties, and created a Cancer Drug database. The database was created utilizing a commercially available software platform called the KnowItAll® Informatics System. We chose drugs on the basis of the functional groups present in their chemical structure and on the drug's documented physicochemical parameters. This database could be used to evaluate Structure Activity Relationships (SARs) and one could also use this database to analyze or predict a chemotherapy compounds' missing pharmacokinetic properties.
* - You must be running the latest version of Java for the images below to appear. You can download the software for free from here (Windows) or run software update (Mac).
ID |
Structure* |
Name |
Molecular Weight |
Formula |
Water Solubility(mg/ml) |
Comments |
Synonyms |
Tradename |
Classification I |
Mutagenicity |
Teratogenicity |
Neurotoxicity |
Oncogenicity |
pKa.1 |
Bioavailability |
Elimination (Half-Life) |
Plasma Protein Binding |
Volume Distribution |
Rate of Absorption |
IUPAC Name |
Classification II |
| CD:00001 | 9-cis-retinoic acid | 300.44 | C20 H28 O2 | 0.01 | Gel | alitretinoin | Panretin | Endogenous retinoid | 0 | 0 | Endogenous retinoid | ||||||||||
| CD:00002 | N-[4-(acridin-9-ylamino)-3-methoxyphenyl 1]-methane sulfonamide | 393.46 | C21 H19 N3 O3 S | 0.001 | Injection | amsacrine, AMSA, acridinyl anisidide, Cain's Acridine | Amsa P-D | Potent cytotoxic agent | 0 | 0 | 8 - 9 | 96 - 98 | 0 | Potent cytotoxic agent | |||||||
| CD:00003 | 4-amino-1-B-D-ribofuranosyl-s-triazin-2(1H)-one | 244.21 | C8 H12 N4 O5 | 0.001 | Injection | azacitidine, 5-AC, 5-azacytidine, azacytidine, ladakamycin | Vidaza, Mylosar | Nucleoside metabolic inhibitor | 0 | 0 | 89 | 4 | 0.714 - 1.46 | Nucleoside metabolic inhibitor | |||||||
| CD:00004 | 1H-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1 methyl-, monohydrochloride | 394.73 | C16 H22 Cl3 N3 O2 | Injection | bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride | Treanda | Alkylating drug | 0 | 0 | 100 | 3 | 94 - 96 | 0.357 | Alkylating drug | |||||||
| CD:00005 | [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid | 384.24 | C19 H25 B N4 O4 | 3.3 - 3.8 | Injection | bortezomib | Velcade | Antineoplastic agent | 1 | 0 | 100 | 40 - 108 | Antineoplastic agent | ||||||||
| CD:00006 | 1,4-butanediol dimethanesulfonate | 246.29 | C6 H14 O6 S2 | Tablets | busulfan, BSF, Bussulfam, Busulfanum, busulphan, glyzophrol, methanesulfonic acid, tetramethylene ester, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Sulfabutin, tetramethylene bis(methanesulfonate) | Myleran, Busulfex | Bifunctional alkylating agent | 0 | 0 | Bifunctional alkylating agent | |||||||||||
| CD:00007 | 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine | 359.35 | C15 H22 F N3 O6 | 26 | Tablets | capecitabine | Xeloda | Fluoropyrimidine carbomate with antineoplastic activity | 0 | 0 | 60 | Fluoropyrimidine carbomate with antineoplastic activity | |||||||||
| CD:00008 | 4-[bis(2-chlorethyl)amino]benzenebutanoic acid | 304.22 | C14 H19 Cl2 N O2 | Tablets | chlorambucil, chlorambucilum, chloraminophen, Chlorbutin, chlorbutine, chlorbutinum, chloroambucil, chlorobutin, chlorobutine, Leukersan, Leukoran, Lympholysin, phenylbutyric acid nitrogen mustard | Leukeran, Ambochlorin, Amboclorin, Linfolizin | Bifunctional alkylating agent of the nitrogen mustard type | 0 | 0 | 5.8 | 1.5 | 99 | Bifunctional alkylating agent of the nitrogen mustard type | ||||||||
| CD:00009 | 2-chloro-6-amino-9-(2-deoxy-B-D-erythropento-furanosyl) | 285.69 | C10 H12 Cl N5 O3 | Injection | cladribine, Cladribina | Leustatin | Synthetic antineoplastic agent | 0 | 0 | 100 | 5.4 | 20 | Synthetic antineoplastic agent | ||||||||
| CD:00010 | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate | 506.02 | C22 H28 Cl N7 O3 S | 0 | Tablets | dasatinib | Sprycel | Kinase inhibitor | 0 | 0 | Kinase inhibitor | ||||||||||
| CD:00011 | (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione | 268.27 | C11 H16 N4 O4 | 0.001 | Injection | dexrazoxane, dexrazoxane hydrochloride | dexrazoxane | Potent intracellular chelating agent | 0 | 0 | 2.1 | 100 | 2.1 - 2.5 | 0 | 0.32 | Potent intracellular chelating agent | |||||
| CD:00012 | (2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5B-20-epoxy-1,2a, 4, 7B, 10B, 13a-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate | 861.94 | C43 H59 N O17 | 0.001 | Injection concentrate | docetaxel | Taxotere | Antineoplastic agent | 0 | 0 | 94 | 1.6 | Antineoplastic agent | ||||||||
| CD:00013 | (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-z-L-lyxo-hexopyranosyl)-oxy)-8-glycolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5, 12-naphthacenedione hydrochloride [25316-40-9] | 579.99 | C27 H30 Cl N O11 | Injection | doxorubicin hydrochloride, ADR, chloridrato de doxorrubicina | Rubex (foreign name), Adriamycin PFS, Adriamycin RDF | Cytotoxic anthracycline antibiotic | 0 | 0 | 100 | 12 - 18.5 | Cytotoxic anthracycline antibiotic | |||||||||
| CD:00014 | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine | 429.9 | C22 H24 Cl N3 O4 | Tablets | erlotinib, erlotinib hydrochloride | Tarceva | Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor | 0 | 0 | 36.2 | Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor | ||||||||||
| CD:00015 | 4'-demethylepipodophyllotoxin 9-[4,6-0-(R)-ethylidene-B-D-glucopyranoside] | 588.57 | C29 H32 O13 | 0.001 | Injection | etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, epipodophyllotoxin, VP-16 | Toposar, VePesid | Semisynthetic derivative of podophyllotoxin | 0 | 0 | 100 | 97 | Semisynthetic derivative of podophyllotoxin | ||||||||
| CD:00016 | 5-fluoro-2,4 (1H,3H)-pyrimidinedione | 130.08 | C4 H3 F N2 O2 | 0.001 | Injection | fluorouracil, 5-fluorouracil, 5-Fluracil, Fluoro Uracil, Fluouracil, FU | Adrucil, Efudex, Fluoroplex | Antineoplastic antimetabolite | 0 | 0 | 100 | Antineoplastic antimetabolite | |||||||||
| CD:00018 | acetic acid;N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrolidin-1-y]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropane-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl}amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide. | 1329.48 | C61 H88 N18 O16 | 1000 | injection | goserelin, goserelin acetate | Zoladex | Potent inhibitor of pituitary gonadotropin secretion | 1 | 0 | 4.2 - 12.1 | 27.3 | Potent inhibitor of pituitary gonadotropin secretion | ||||||||
| CD:00019 | pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11B) | 484.52 | C25 H33 Na O8 | 1000 | Injection | hydrocortisone sodium succinate, hydrocortisone sodium phosphate, Hydrocortisone, cortisone | Solu-Cortef, Ala-Cort, Hydrocortone phosphate, Hydrocort Acetate, Lanacort, Cortef | Anti-inflammatory adrenocortical steroid | 0 | 0 | Anti-inflammatory adrenocortical steroid | ||||||||||
| CD:00020 | hydroxyurea | 76.05 | C H4 N2 O2 | Capsules | hydroxyurea, HYD, Hydroxycarbamide, Hydurea | Droxia, Hydrea | 0 | 0 | 3 - 4 | 100 | |||||||||||
| CD:00021 | (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxol H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate | 677.19 | C33 H45 Cl N4 O9 | 0.01 | Injection | irinotecan hydrochloride, camptothecin-11, irinotecan, irinotecan HCl | Camptosar | Antineoplastic agent of the topoisomerase I inhibitor class | 0 | 0 | 100 | 5.8 - 11.7 | 30 - 68 | 1.5 - 3.3 | Antineoplastic agent of the topoisomerase I inhibitor class | ||||||
| CD:00022 | 13-cis-retinoic acid | 300.44 | C20 H28 O2 | Capsule, liquid filled | isotretinoin, 13-cis-retinoic acid, 13-cis-vitamin A acid, cis-retinoic acid, isotretinoinum, neovitamin A, Neovitamin A Acid | Accutane, Amnesteem, Cistane, Claravis, Sotret | Retinoid which inhibits sebaceous gland function and keratinization | 0 | 1 | Retinoid which inhibits sebaceous gland function and keratinization | |||||||||||
| CD:00023 | N-(3-chloro-4-{[(3-fluorophenyl)methyl]pxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine bis(4-methylbenzenesulfonate) monohydrate | 943.47 | C43 H44 Cl F N4 O11 S3 | 0.007 | Tablets | lapatinib, lapatinib ditosylate | Tykerb | Kinase inhibitor | 0 | 0 | 90 | 99.9 | Kinase inhibitor | ||||||||
| CD:00024 | 3-(4-amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2,6-dione | 259.26 | C13 H13 N3 O3 | Capsules | lenalidomide, IMiD-1 | Revlimid | Immunomodulatory agent with anti-angiogenic and anti-neoplastic properties | 0 | 0 | Immunomodulatory agent with anti-angiogenic and anti-neoplastic properties | |||||||||||
| CD:00025 | 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile | 285.31 | C17 H11 N5 | 1000 | Tablets | letrozole | Femara | Nonsteroidal aromatase inhibitor | 0 | 0 | 2 | 1.9 | Nonsteroidal aromatase inhibitor | ||||||||
| CD:00026 | N-[p-[[[(6RS)-2- amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1) | 511.51 | C20 H21 Ca N7 O7 | Injection | leucovorin calcium, calcium (6S)-folinate, calcium folinate, CFR, citrovorum factor, folinate calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Leucovorin, LV | Wellcovorin | Chemically reduced derivative of folic acid | 0 | 0 | 97 | 6.2 | 15 | Chemically reduced derivative of folic acid | ||||||||
| CD:00027 | 5-oxo-l-prolyl-l-histidyl-l-tryptrophyl-l-tyrosyl-D-leucyl-l-arginyl-N-ethyl-l-prolinamide acetate | C59 H84 N16 O12 | Depot Suspension | leuprolide acetate, Leuprorelin, Leuprorelin Acetate | Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Viadur | Potent inhibitor of gonadotropin secretion | 0 | 1 | 1 | 3 | 0.38 | Potent inhibitor of gonadotropin secretion | |||||||||
| CD:00028 | 1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea | 233.7 | C9 H16 Cl N3 O2 | 0.001 | Capsules | lomustine, Lomustinum | CeeNU | Nitrosourea | 0 | 0 | 1.6 | 50 | 100 | Nitrosourea | |||||||
| CD:00029 | 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride | 192.52 | C5 H12 Cl3 N | Injection | mechlorethamine HCl, chloramin, chlorethamine HCl, chlorethamine hydrochloride, chlorethazine, chlorethazine hydrochloride, chlormethine, chlormethine hydrochloride, chloromethine HCl, mechlorethamine, mechlorethamine HCl, methylchlorethamine, Mustard, mustargen HCl, mustargen hydrochloride, Mustine, NH-2, N-Lost | Mustargen | Antineoplastic nitrogen mustard | 1 | 1 | 1 | Antineoplastic nitrogen mustard | ||||||||||
| CD:00030 | 17 a-acetyloxy-6-methylpregna-4,6-diene-3,20-dione | 384.52 | C24 H32 O4 | 0.002 | Tablets | megestrol acetate | Megace, Ovaban, Pallace | Antineoplastic and progestational drug | 0 | 0 | Antineoplastic and progestational drug | ||||||||||
| CD:00031 | 4-[bis(2-chloroethyl)amino]-L-phenylalanine | 305.2 | C13 H18 Cl2 N2 O2 | 0.001 | Injection | melphalan hydrochloride, alanine nitrogen mustard, L-phenylalanine mustard, L-Sarcolysin, L-sarcolysin phenylalanine mustard, L-sarcolysine, phenylalanine mustard, phenylalanine nitrogen mustard | Alkeran | Bifunctional alkylating agent | 0 | 0 | 2.5 | 100 | 60 - 90 | 0.5 | Bifunctional alkylating agent | ||||||
| CD:00032 | 1,7-dihydro-6H-purine-6-thione monohydrate | 170.19 | C5 H6 N4 O S | Tablets | mercaptopurine, 6 Thiohypoxanthine, 6 Thiopurine, 6-mercaptopurine, 6-Mercaptopurine Monohydrate, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, Azathiopurine, Leupurin, Mercapurin, Mern, Purimethol | Purinethol, Mercaptopurinum | Analogue of the purine bases adenine and hypoxanthine | 0 | 0 | 5 - 37 | 1 - 2 | 19 | Analogue of the purine bases adenine and hypoxanthine | ||||||||
| CD:00033 | N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid | 454.45 | C20 H22 N8 O5 | Tablets | methotrexate, alpha-methopterin, amethopterin, Methotrexatum, methylaminopterin, Metotrexato, methotrexate sodium | Rheumatrex, Abitrexate, Folex, Folex PFS, Methotrexate LPF, Mexate, Mexate-AQ | Antimetabolite which inhibits dihydrofolic acid reductase | 0 | 0 | 60 | 0.7 - 5.8 | Antimetabolite which inhibits dihydrofolic acid reductase | |||||||||
| CD:00034 | 9-methoxy-7H-furo[3,2-g][1]-benzopyran-7-one | 216.19 | C12 H8 O4 | methoxsalen, 8-methoxypsoralen, Methoxypsoralen | Ammoidin, Oxsoralen, Oxsoralen-Ultra, Uvadex, Xanthotoxin | 0 | 0 | ||||||||||||||
| CD:00035 | pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-,(6a,11B) | 416.51 | C24 H32 O6 | 0.001 | Injectable Suspension | methylprednisolone acetate | Duralone | 0 | 0 | ||||||||||||
| CD:00037 | 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-azirino[2',3':4]pyrrolo[1,2-a]indole-47-dione carbamate(ester). | 334.33 | C15 H18 N4 O5 | Injection | mitomycin, mitomycin C, mitomycine C, mitomycin-X | Mitozytrex, Mutamycin | Selective inhibitor of DNA synthesis | 0 | 0 | 100 | 0.7 | Selective inhibitor of DNA synthesis | |||||||||
| CD:00038 | 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane | 320.05 | C14 H10 Cl4 | Tablets | mitotane, Chloditan, Chlodithane, Khloditan, Mytotan, o,p'-DDD, Ortho,para-DDD | Lysodren | Adrenal cytotoxic agent | 0 | 0 | Adrenal cytotoxic agent | |||||||||||
| CD:00039 | 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl) amino]ethyl]amino-9,10-anthracenedione dihydrochloride | 517.41 | C22 H30 Cl2 N4 O6 | Injection Concentrate | mitoxantrone, dihydroxyanthracenedione, dihydroxyanthracenedione dihydrochloride, mitoxantrone dihydrochloride, mitoxantrone HCl, mitozantrone hydrochloride | Novantrone | Synthetic antineoplastic anthracenedione | 0 | 0 | 100 | 75 | 78 | 14 | Synthetic antineoplastic anthracenedione | |||||||
| CD:00040 | 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione | 317.22 | C12 H10 F3 N3 O4 | 0.01 | Tablets | nilutamide | Nilandron | Nonsteroidal, orally active antiandrogen | 0 | 0 | 38 - 59.1 | 50 | Nonsteroidal, orally active antiandrogen | ||||||||
| CD:00041 | L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2->7)-disulfide; [R-(R*,R*)] acetate salt | 1019.24 | C49 H66 N10 O10 S2 | Injection, solution | octreotide acetate, Longastatin | Sandostatin, Sandostatin Lar Depot | 0 | 0 | 1.7 - 1.9 | 65 | 0.2 | ||||||||||
| CD:00042 | 5B,20-Epoxy-1,2a,4,7B,10B,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine | 853.92 | C47 H51 N O14 | 0 | Injection | paclitaxel | Taxol | Novel antimicrotubule agent | 0 | 0 | 100 | 89 - 98 | 3.2 - 9.8 | Novel antimicrotubule agent | |||||||
| CD:00044 | (R)-3-(2-deoxy- -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ | 268.27 | C11 H16 N4 O4 | Injection | pentostatin, 2'-deoxycoformycin, co-vidarabine, deoxycoformycin, pentostatine | Nipent | Potent inhibitor of the enzyme adenosine deaminase | 0 | 0 | 0.18 | 4 | Potent inhibitor of the enzyme adenosine deaminase | |||||||||
| CD:00045 | l,1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane | 502.79 | C28 H54 N8 | Injection | plerixafor | Mozobil | Hematopoietic stem cell mobilizer | 0 | 0 | 3 - 5 | 58 | 0.3 | Hematopoietic stem cell mobilizer | ||||||||
| CD:00046 | pregna-1, 4-diene-3,20-dione, 11, 17-dihydroxy-21-(phosphonooxy)-, disodium salt, (11B)- | 484.39 | C21 H27 Na2 O8 P | 1000 | Tablets, orally disintegrating | prednisolone sodium phosphate | prednisolone sodium phosphate | Synthetic adrenocortical steroid drug | 0 | 0 | 70 - 90 | Synthetic adrenocortical steroid drug | |||||||||
| CD:00047 | N-isopropyl-a-(2-methylhydrazin0)-p-toluamide monohydrochloride | 257.76 | C12 H20 Cl N3 O | 1000 | Capsules | procarbazine hydrochloride, Ibenzmethyzin, ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, MIH, MIH hydrochloride, PCB Hydrochloride, PCZ, Procarbazin | Matulane | Hydrazine derivative antineoplastic agent | 0 | 0 | 0.16 | Hydrazine derivative antineoplastic agent | |||||||||
| CD:00049 | N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid | 458.49 | C21 H22 N4 O6 S | Injection | raltitrexed, raltitrexed disodium | Tomudex | Quinazoline folate analogue that selectively inhibits thymidylate synthase (TS) | 0 | 0 | 100 | 0.25 - 0.5 | 80 | Quinazoline folate analogue that selectively inhibits thymidylate synthase (TS) | ||||||||
| CD:00050 | 4-(4-{3-[4-Chloro-3-(trifluoromehtyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate | 637.03 | C28 H24 Cl F3 N4 O6 S | 0.001 | sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt | Nexavar | Kinase inhibitor | 0 | 1 | 38 - 49 | 25 - 48 | 99.5 | Kinase inhibitor | ||||||||
| CD:00051 | 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-a(and B)-D-glucopyranose | 265.22 | C8 H15 N3 O7 | 1000 | Sterile Powder | streptozocin, streptozotocin | Zanosar | Synthetic antineoplastic agent | 0 | 0 | 100 | Synthetic antineoplastic agent | |||||||||
| CD:00052 | Butanedioic acid, hydroxy-, (2S)-, compoound with N-[2-(diethylamino)ethyl]-5-[(Z)-(fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3carboxamide (1:1) | 532.57 | C26 H33 F N4 O7 | 25 | Capsules | sunitinib malate, sunitinib | Sutent | Multi-kinase inhibitor | 0 | 0 | 31.8 | Multi-kinase inhibitor | |||||||||
| CD:00053 | (Z)2-[4-(1,2-diphenyl-1-buenyl) phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3- propanetricarboxylate (1:1) | 563.65 | C32 H37 N O8 | 0.5 | Tablets | tamoxifen citrate, Novaldex, tamoxifen, Tamoxifeni Citras | Nolvadex | Nonsteroidal antiestrogen | 0 | 0 | Nonsteroidal antiestrogen | ||||||||||
| CD:00054 | 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide | 194.15 | C6 H6 N6 O2 | Capsules | temozolomide | Temodar, Methazolastone | Imidazotetrazine derivative | 0 | 0 | 1.8 | 15 | 1.4 | Imidazotetrazine derivative | ||||||||
| CD:00055 | (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)- | 1030.3 | C56 H87 N O16 | 0.001 | Injection | temsirolimus, cell cycle inhibitor 779, rapamycin analog CCI-779 | Torisel | Antineoplastic agent | 0 | 0 | 100 | 2.4 | Antineoplastic agent | ||||||||
| CD:00056 | 4-demethylepipodophyllotoxin 9-[4,6-0-(R)-2-thenylidene-B-D-glucopyranoside | 656.66 | C32 H32 O13 S | 0 | Injection | teniposide, Thenvlidene-Lignan-P, Thenylidene-Lignan-P, VM26 | Vumon | 1 | 1 | 100 | 5 | 99 | |||||||||
| CD:00057 | (RS)-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione. | 258.23 | C13 H10 N2 O4 | 0.001 | Capsules | thalidomide, alpha-phthalimidoglutarimide, N-phthaloylglutamimide, N-phthalylglutamic acid imide | Thalomid, Synovir | 0 | 1 | 5 - 7 | 55 - 66 | ||||||||||
| CD:00058 | 2-amino-1,7-dihydro-6H-purine-6-thione | Tablets | thioguanine | Tabloid, Tabloid brand thioguanine, Tioguanine | 0 | 0 | 14 - 46 | 0.4 - 4 | |||||||||||||
| CD:00059 | Tris(1-aziridinyl)phosphine sulfide | 189.22 | C6 H12 N3 P S | Injection | thiotepa, thiophosphamide, thiophosphoramide, triethylene thiophosphoramide, TSPA | Thioplex, Girostan, STEPA, TESPA, Thiofozil, Tifosyl | Cytotoxic agent of the polyfunctional type | 0 | 0 | Cytotoxic agent of the polyfunctional type | |||||||||||
| CD:00060 | (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino [1,2-b]quinoline-3,14-(4H,12H)-dione monohydrochloride | 457.91 | C23 H24 Cl N3 O5 | 1000 | Injection | topotecan hydrochloride, hycamptamine | Hycamtin | Anti-tumor drug with topoisomerase I-inhibitory activity | 0 | 1 | 100 | 2 - 3 | 35 | Anti-tumor drug with topoisomerase I-inhibitory activity | |||||||
| CD:00061 | 2-{p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy}-N,N-dimethylethylamine citrate (1:1) | 598.09 | C32 H36 Cl N O8 | 0.63 | Tablets | toremifene, toremifene citrate | Fareston | Nonsteroidal antiestrogen | 0 | 1 | 8 | Nonsteroidal antiestrogen | |||||||||
| CD:00062 | (2E,4E,6E8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid | 300.44 | C20 H28 O2 | Capsules | tretinoin, all-trans retinoic acid, all-trans vitamin A acid, beta-retinoic acid, retinoic acid, TRA, trans retinoic acid, trans vitamin A acid, tretinoinum, Vitamin A Acid | Vesanoid, Aberel, Aknoten, Avita, Renova, Retin-A, Retin-A MICRO | 1 | 0 | 95 | ||||||||||||
| CD:00063 | (2S-cis)-2-[1,2,3,4, 6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-a-L-lyxo-hexopyranosyl]oxyl]-2-naphthacenyl]-2-oxoethyl pentanoate | 723.65 | C34 H36 F3 N O13 | 0.001 | valrubicin | Valstar | 0 | 0 | 0 | 0.4 - 0.5 | 99 | ||||||||||
| CD:00064 | dimethyl(2B,3B,4B,5a,12B,19a)-15-[(5s,9s)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7,didehydroaspidosprmidine-3,4-dicarboxylate. | 909.06 | C46 H60 N4 O13 S | 1000 | Injection | vinblastine sulfate, Vincaleucoblastine, vinblastine | Velban, Velsar | Stathmokinetic oncolytic agent | 0 | 0 | 100 | 2.4 | 90 | Stathmokinetic oncolytic agent | |||||||
| CD:00065 | methyl(1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate. | 923.04 | C46 H58 N4 O14 S | 1000 | Injection | vincristine sulfate, leurocristine sulfate | Vincasar PFS | Mitotic inhibitor | 1 | 0 | 100 | 19 - 155 | Mitotic inhibitor | ||||||||
| CD:00066 | methyl(5S,7S,9S)-9-[(2B,3B,5a,12B,19a)-3-(aminocarbonyl)-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate. | 852.01 | C43 H57 N5 O11 S | Injection | vindesine, Compound 112531, deacetyl vinblastine carboxamide, desacetylvinblastine amide | Eldisine | Mitotic Inhibitor | 0 | 0 | 100 | 65 - 75 | 8.11 | 24 | Mitotic Inhibitor | |||||||
| CD:00067 | 3',4'-didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2,3-dihydroxybutanedioate (1:2)(salt)] | 1079.12 | C53 H66 N4 O20 | 1000 | Injection | vinorelbine tartrate, navelbine ditartrate, vinorelbine ditartrate | Navelbine | Semi-synthetic vinca alkaloid with antitumor activity | 0 | 0 | 100 | 27.7 - 43.6 | 25.4 - 40.1 | Semi-synthetic vinca alkaloid with antitumor activity | |||||||
| CD:00068 | N-hydroxy-N'-phenyloctanediamide | 264.32 | C14 H20 N2 O3 | 0.001 | Capsules | vorinostat, suberoylanilide hydroxamic acid | Zolinza | Histone deacetylase (HDAC) inhibitor | 0 | 0 | 2 | 71 | Histone deacetylase (HDAC) inhibitor | ||||||||
| CD:00069 | (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate | 290.11 | C5 H12 N2 O8 P2 | 1 | Injection | zoledronic acid, NDC-zoledronate, zoledronate | Zometa | Inhibitor of osteoclastic bone resorption | 1 | 0 | 146 | 22 | Inhibitor of osteoclastic bone resorption | ||||||||
| CD:00071 | 40-O-(2-hydroxyethyl)-rapamycin | 958.24 | C53 H83 N O14 | Tablets | everolimus | Afinitor | Kinase Inhibitor; inhibits mTOR | 0 | 0 | 17 - 73 | 30 | 74 | 80 | Kinase Inhibitor; inhibits mTOR | |||||||
| CD:00072 | 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one monohydrochloride monohydrate. | 310.57 | C10 H10 Cl3 N3 O2 | 0.01 | Capsules | anagrelide HCl | Agrylin | Platelet reducing agent | 0 | 0 | 1.3 | 70 | Platelet reducing agent | ||||||||
| CD:00074 | 1,3-Benzenediacetonitrile,a,a,a',a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl) | 293.37 | C17 H19 N5 | 0.5 | Tablets | anastrazole | Arimidex | Aromataze inhibitor | 0 | 1 | 50 | 40 | 83 - 85 | Aromataze inhibitor | |||||||
| CD:00075 | 6-methylenandrosta-1,4-diene-3,17-dione. | 296.41 | C20 H24 O2 | 0 | Tablets | exemestane | Aromasin | Aromataze inhibitor | 0 | 0 | 24 | 90 | 42 | Aromataze inhibitor | |||||||
| CD:00076 | 2-amino--9-B-Darabinofuranoslyl-6-methoxy-9H-purine. | 297.27 | C11 H15 N5 O5 | 0.01 | Injection | melarabine | Arranon | DNA synthesis inhibitor | 0 | 0 | 0.5 | 25 | 0 - 216 | DNA synthesis inhibitor | |||||||
| CD:00077 | propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-). | 430.37 | C18 H14 F4 N2 O4 S | 0 | Tablets | bicalutamide | Casodex | Nonsteroidal antiandrogen | 0 | 0 | 0 | 5.8 | 96 | Nonsteroidal antiandrogen | |||||||
| CD:00078 | 2-amino-4,6-dimethyl-3-oxo-N,N"-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide. | 1255.44 | C62 H86 N12 O16 | Injection | dactinomycin | Cosmegen | RNA synthesis inhibitor | 1 | 1 | 1 | 36 | RNA synthesis inhibitor | |||||||||
| CD:00079 | 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine2-oxide monohydrate. | 261.09 | C7 H15 Cl2 N2 O2 P | 1000 | cyclophosphamide | Cytoxan | Crosslinkage of DNA | 0 | 1 | 75 | 3 - 12 | Crosslinkage of DNA | |||||||||
| CD:00080 | 4-amino-1(2-deoxy-B-D-erythro-pentofuranosyl)-1,3,5-trizan-2(1H)-one. | 228.21 | C8 H12 N4 O4 | 0.001 | decitabine | Dacogen | Inhibitor of DNA methyltransferase | 0 | 0 | 0.51 | 1 | Inhibitor of DNA methyltransferase | |||||||||
| CD:00081 | 4-amino-1-B-D-arabinofuranosyl-2(1H)-pyrimidinone. | 243.22 | C9 H13 N3 O5 | cytarabine | Depocyt | Inhibits DNA polymerase | 1 | 0 | 5.9 - 82.4 | Inhibits DNA polymerase | |||||||||||
| CD:00082 | methanone,[6-hydroxy-2(4-hydroxyphenyl)bezo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride. | 510.05 | C28 H28 Cl N O4 S | 0.001 | raloxifene | Evista | Selective ER modulator | 0 | 0 | 2 | 27.7 | 95 | 2348 | 60 | Selective ER modulator | ||||||
| CD:00083 | 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)-triene-3,17-beta-diol. | 606.78 | C32 H47 F5 O3 S | fulvestrant | Faslodex | Estrogen receptor antagonist | 0 | 0 | 40 | 99 | 0.04 - 0.07 | Estrogen receptor antagonist | |||||||||
| CD:00084 | 9H-Purin-6-amine,2-fluoro-9-(5-0-phosphono-B-D-arabino-furanosyl)(2-fluoro-ara-AMP). | 365.21 | C10 H13 F N5 O7 P | 0.01 | Injection | fludrabine | Fludara | DNA synthesis inhibitor | 0 | 0 | 20 | 19 - 29 | DNA synthesis inhibitor | ||||||||
| CD:00085 | 2'-deoxy-2',2'-difluorocytidine monohydrochloride(B-isomer). | 263.2 | C9 H11 F2 N3 O4 | 1000 | gemcitabine | Gemzar | DNA synthesis inhibitor | 0 | 0 | 42 - 638 | 0 | 0.7 - 5.2 | DNA synthesis inhibitor | ||||||||
| CD:00086 | 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methane-sulfonate. | 589.71 | C30 H35 N7 O4 S | 0.01 | imatinib mesylate | Gleevec | Kinase inhibitor | 1 | 1 | 1 | 98 | 18 | 95 | Kinase inhibitor | |||||||
| CD:00087 | N,N,N',N',N",N" -hexamethyl-1,3,5-triazine-2,4,6-triamine | 210.28 | C9 H18 N6 | altretamine | Hexalen | Synthetic cytotoxic agent | 0 | 0 | 4.7 - 10.2 | 0 - 50 | 90 | Synthetic cytotoxic agent | |||||||||
| CD:00088 | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxane-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione. | 533.96 | C26 H28 Cl N O9 | idarubicin HCl | Idamycin | Nucleic acid synthesis inhibitor via Topoisomerase II | 0 | 0 | 22 | 97 | Nucleic acid synthesis inhibitor via Topoisomerase II | ||||||||||
| CD:00089 | (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.10] heptadecane-5,9-dione. | 506.7 | C27 H42 N2 O5 S | ixabepilone | Ixempra | Microtubule inhibitor | 0 | 0 | 20 | 52 | 67 - 77 | 14.3 | Microtubule inhibitor | ||||||||
| CD:00090 | acetyl-D-B-naphthylalanyl-D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L-N-methyl-tyrosyl-D-asparagyl-L-leucyl-L-N(e)-isopropyl-lysyl-L-prolyl-D-alanyl-amide. | 1416.08 | C72 H95 Cl N14 O14 | abarelix | Plenaxis | GnRh inhibitor | 0 | 0 | 10 - 16.4 | 96 - 99 | 38.4 - 80.6 | GnRh inhibitor | |||||||||
| CD:00091 | 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic | 348.48 | C24 H28 O2 | 0 | bexarotene | Targretin | Retinoic acid receptor inhibitor | 0 | 0 | 7 | 99 | 2 | N.A. | Retinoic acid receptor inhibitor |
This project was supported by DE-NIH NCRR INBRE grant number 2 P20 RR016472-10 through the University of Delaware and a NASA Grant NNG05GO92H through the Delaware Space Grant College and Fellowship Program.